Pancreatic Surgery with Vascular Reconstruction in Patients with Locally Advanced Pancreatic Neuroendocrine Tumors

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2013 May 15

PMID 23670519

Citations 14

Authors

Sven-Petter Haugvik

Knut Jorgen Labori

Anne Waage

Pal-Dag Line

Oystein Mathisen

Ivar Prydz Gladhaug

Affiliations

Soon will be listed here.

Abstract

Introduction: Pancreatic neuroendocrine tumors (PNET) are rare neoplasms with better prognosis than most pancreatic malignancies. Surgery of locally advanced PNET remains controversial, and the role of vascular reconstruction in this patient group has yet to be defined. The aim of this study was to evaluate the feasibility and outcome of pancreatic resections with vascular reconstruction in patients with locally advanced PNET.

Methods: Retrospective analysis of patients who underwent pancreatic surgery with vascular reconstruction for locally advanced PNET at a single institution. Furthermore, a review of the relevant literature on the topic was performed.

Results: Seven patients who had undergone vascular reconstruction for locally advanced PNET were identified. Four patients had liver metastases at time of surgery. Postoperative complications developed in four patients with no mortality. Median follow-up time of all patients was 21 (range, 3-58) months. Three patients had disease in remission after 58, 42 and 3 months, respectively. One patient died 35 months postoperatively due to progressive disease, whereas three patients had progression of disease after 21, 9, and 4 months postoperatively.

Conclusion: Pancreatic surgery with vascular reconstruction in patients with locally advanced PNET is feasible with acceptable outcome.

Citing Articles

Pancreatoduodenectomy En Bloc With Superior Mesenteric Artery Resection for Borderline Resectable Pancreatic Cancer - A Case Report and Literature Review.

Petrea S, Bacalbasa N, Balescu I, Diaconu C, Stiru O, Cauni V Cancer Diagn Progn. 2023; 3(1):135-138.

PMID: 36632596 PMC: 9801448. DOI: 10.21873/cdp.10191.

Surgical Indications and Outcomes of Resection for Pancreatic Neuroendocrine Tumors with Vascular Involvement.

Li A, Visser B, Dua M Cancers (Basel). 2022; 14(9).

PMID: 35565442 PMC: 9103421. DOI: 10.3390/cancers14092312.

Induction therapy with Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients.

Minczeles N, van Eijck C, van Gils M, van Velthuysen M, Nieveen van Dijkum E, Feelders R Eur J Nucl Med Mol Imaging. 2022; 49(9):3203-3214.

PMID: 35230492 PMC: 9250460. DOI: 10.1007/s00259-022-05734-8.

What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review.

Frey S, Mirallie E, Le Bras M, Regenet N Cancers (Basel). 2021; 13(23).

PMID: 34885063 PMC: 8656750. DOI: 10.3390/cancers13235954.

Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.

Titan A, Norton J, Fisher A, Foster D, Harris E, Worhunsky D JAMA Netw Open. 2020; 3(11):e2024318.

PMID: 33146734 PMC: 7643030. DOI: 10.1001/jamanetworkopen.2020.24318.

References

Roder J, Stein H, Siewert J . Carcinoma of the periampullary region: who benefits from portal vein resection?. Am J Surg. 1996; 171(1):170-4; discussion 174-5. DOI: 10.1016/S0002-9610(99)80094-4. View

Fuhrman G, Leach S, Staley C, Cusack J, Charnsangavej C, Cleary K . Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg. 1996; 223(2):154-62. PMC: 1235091. DOI: 10.1097/00000658-199602000-00007. View

Porembka M, Hall B, Hirbe M, Strasberg S . Quantitative weighting of postoperative complications based on the accordion severity grading system: demonstration of potential impact using the american college of surgeons national surgical quality improvement program. J Am Coll Surg. 2010; 210(3):286-98. DOI: 10.1016/j.jamcollsurg.2009.12.004. View

Siriwardana H, Siriwardena A . Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg. 2006; 93(6):662-73. DOI: 10.1002/bjs.5368. View

Hellman P, Andersson M, Rastad J, Juhlin C, Karacagil S, Eriksson B . Surgical strategy for large or malignant endocrine pancreatic tumors. World J Surg. 2000; 24(11):1353-60. DOI: 10.1007/s002680010224. View

Norton J, Kivlen M, Li M, Schneider D, Chuter T, Jensen R . Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg. 2003; 138(8):859-66. DOI: 10.1001/archsurg.138.8.859. View

Akatsu T, Aiura K, Shimazu M, Ueda M, Wakabayashi G, Tanabe M . Successful pancreatectomy with en-bloc resection of the celiac artery and portal vein for pancreatic endocrine carcinoma. Hepatogastroenterology. 2007; 54(76):1269-71. View

Solorzano C, Lee J, Pisters P, Vauthey J, Ayers G, Jean M . Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001; 130(6):1078-85. DOI: 10.1067/msy.2001.118367. View

van Geenen R, Ten Kate F, de Wit L, van Gulik T, Obertop H, Gouma D . Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy. Surgery. 2001; 129(2):158-63. DOI: 10.1067/msy.2001.110221. View

10.

Hauso O, Gustafsson B, Kidd M, Waldum H, Drozdov I, Chan A . Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008; 113(10):2655-64. DOI: 10.1002/cncr.23883. View

11.

Bedirli A, Patiroglu T, Sakrak O, Aritas Y . Portal vein resection for a portal vein thrombus caused by nonfunctioning islet cell carcinoma: report of a case. Surg Today. 2004; 34(9):802-4. DOI: 10.1007/s00595-004-2806-5. View

12.

Yamato H, Kawakami H, Kuwatani M, Shinada K, Kondo S, Kubota K . Pancreatic carcinoma associated with portal vein tumor thrombus: three case reports. Intern Med. 2009; 48(3):143-50. DOI: 10.2169/internalmedicine.48.1049. View

13.

Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

14.

Ochiai T, Masuda T, Nishizawa M, Ito H, Igari K, Aihara A . Curative resection of a huge malignant pancreatic endocrine tumor by pancreatoduodenectomy with portal and superior mesenteric vein resection and reconstruction using the right ovarian vein: report of a case. Surg Today. 2011; 41(9):1260-5. DOI: 10.1007/s00595-010-4466-y. View

15.

Hodul P, Strosberg J, Kvols L . Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?. Cancer Control. 2008; 15(4):314-21. DOI: 10.1177/107327480801500406. View

16.

Falconi M, Bartsch D, Eriksson B, Kloppel G, Lopes J, OConnor J . ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012; 95(2):120-34. DOI: 10.1159/000335587. View

17.

Tsuchikawa T, Kondo S, Hirano S, Tanaka E, Kawasaki R, Kato K . Distal pancreatectomy and portal vein resection without vascular reconstruction for endocrine tumors with massive intraportal growth: report of a case. Hepatogastroenterology. 2011; 58(107-108):1029-31. View

18.

Norton J, Harris E, Chen Y, Visser B, Poultsides G, Kunz P . Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg. 2011; 146(6):724-32. PMC: 3122162. DOI: 10.1001/archsurg.2011.129. View

19.

Sakamoto E, Hasegawa H, Ogiso S, Igami T, Mori T, Mizuno T . Curative resection for a pancreatic endocrine carcinoma involving the portal vein. Hepatogastroenterology. 2004; 51(60):1849-51. View

20.

Harrison L, Klimstra D, Brennan M . Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection?. Ann Surg. 1996; 224(3):342-7; discussion 347-9. PMC: 1235378. DOI: 10.1097/00000658-199609000-00010. View